Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;8(2):337-346.
doi: 10.21037/jgo.2016.09.06.

Operative microwave ablation for hepatocellular carcinoma: a single center retrospective review of 219 patients

Affiliations

Operative microwave ablation for hepatocellular carcinoma: a single center retrospective review of 219 patients

Erin H Baker et al. J Gastrointest Oncol. 2017 Apr.

Abstract

Background: Microwave ablation (MWA) of hepatocellular carcinoma (HCC) offers local regional treatment that can be safely and effectively performed, even in patients with advanced liver disease. We update results from our group's previous analysis of operative MWA for HCC.

Methods: Retrospective review was performed of all patients who underwent operative MWA for HCC from 2007-2014. Patient demographics, operative characteristics and complications were recorded. Follow up imaging was reviewed to determine rates of complete ablation, local, regional and metastatic recurrence.

Results: Two hundred and nineteen patients were included with a total of 340 tumors treated with operative MWA. Median tumor size was 3.2 cm (range, 1-6 cm). Cirrhosis was present in 89.5% of patients, 60.7% had hepatitis C, and 8.2% had hepatitis B. Thirty-five point nine percent were Child-Pugh class B/C. Ninety-six point eight percent of MWA procedures were performed laparoscopically. Four deaths occurred within 30 days (1.8%). Clavien-Dindo grade III complications occurred in 3.2% of patients. Complete ablation was identified in 97.1% of tumors, with local recurrence rates of 8.5% at 10.9 months median follow up (0-80 months). Regional recurrence occurred in 34.8% of patients at 10.9 months median follow up and metastatic recurrence was seen in 8.1% of patients. One year overall survival was 80.0% and 2-year survival was 61.5%.

Conclusions: We propose that laparoscopic MWA offers a low morbidity approach for treatment of HCC affording low rates of local recurrence even for patients with significant underlying liver dysfunction. This large series offers insight into outcomes of this modality as definitive treatment for patients with HCC.

Keywords: Microwave ablation (MWA); hepatocellular carcinoma (HCC); outcomes.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Number of MWA procedures performed per year at Carolinas Medical Center during the study period. MWA, microwave ablation.
Figure 2
Figure 2
Tumor location by hepatic segment.
Figure 3
Figure 3
Kaplan-Meier analysis of (A) overall survival, (B) by Child-Pugh class A or B status, (C) by tumor number greater than or less than one, (D) by largest tumor size greater than or less than 3 cm. Censored patients are marked (+).

References

    1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-27. 10.1056/NEJMra1001683 - DOI - PubMed
    1. Azzam AZ. Liver transplantation as a management of hepatocellular carcinoma. World J Hepatol 2015;7:1347-54. 10.4254/wjh.v7.i10.1347 - DOI - PMC - PubMed
    1. Feng K, Ma KS. Value of radiofrequency ablation in the treatment of hepatocellular carcinoma. World J Gastroenterol 2014;20:5987-98. 10.3748/wjg.v20.i20.5987 - DOI - PMC - PubMed
    1. He ZX, Xiang P, Gong JP, et al. Radiofrequency ablation versus resection for Barcelona clinic liver cancer very early/early stage hepatocellular carcinoma: a systematic review. Ther Clin Risk Manag 2016;12:295-303. - PMC - PubMed
    1. Yang W, Yan K, Goldberg SN, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment. World J Gastroenterol 2016;22:2993-3005. 10.3748/wjg.v22.i10.2993 - DOI - PMC - PubMed

LinkOut - more resources